3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
13
Stomach Neoplasms
7
Pancreatic Neoplasms
7
Colonic Neoplasms
4
Rectal Neoplasms
3
Pain, Postoperative
3
Neurotoxicity Syndromes
3
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Surgical Wound Infection
1
Stomatitis
1
Sigmoid Neoplasms
1
Recurrence
1
Ovarian Neoplasms
1
Neutropenia
1
Neoplasms
1
Melanoma
1
Lung Injury
1
Ileus
1
Hidrocystoma
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Febrile Neutropenia
1
Fatigue
1
Esophageal Atresia
1
Endometrial Neoplasms
1
Interventions
Imatinib Mesylate
71
Sunitinib
31
regorafenib
17
nilotinib
15
ripretinib
13
avapritinib
7
Laparoscopy
5
Ipilimumab
5
Dasatinib
5
spartalizumab
4
CTLA-4 Antigen
4
Blood Specimen Collection
4
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4
pexidartinib
3
pazopanib
3
binimetinib
3
Temozolomide
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Paclitaxel
3
Oxaliplatin
3
Observation
3
Nivolumab
3
Midazolam
3
Leucovorin
3
Gemcitabine
3
Biopsy
3
Bevacizumab
3
trametinib
2
tanespimycin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
Sodium Chloride
×
Gastrointestinal
×
Clear all
NCT01265810
2017-11-13
COMTT
Impaqtt Foundation
Phase 3
Completed
64 enrolled